Sangamo is a biopharma company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs.
Sangamo – zinc finger proteins therapeutics
Sangamo developed a proprietary technology platform enabling specific regulation of gene expression and gene modification. The basis of this technology is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs) which can be engineered to drive desired therapeutic outcomes. Sangamo’s primary mission is to develop ZFP Therapeutics. Engineered ZFPs can be linked to functional domains that normally activate or repress gene expression to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. Engineered ZFNs can modify a cell’s DNA at a precise location. Sangamo has several ZFP Therapeutic programs under development, including programs in hemophilia and Huntington’s disease. As part of its acquisition of Ceregene Inc., Sangamo acquired a fully-enrolled, double-blind, placebo-controlled Phase 2 trial to evaluate NGF-AAV (CERE-110) in Alzheimer’s disease. CERE-110 uses adeno-associated virus (AAV) to deliver the gene for nerve growth factor (NGF) into the brain of subjects with mild to moderate Alzheimers disease with the aim of helping nerve cells survive and function better. Moreover, SB-313 is an off-the-shelf cytotoxic T-cell product made resistant to glucocorticoid steroids using ZFN-mediated modification of the glucocorticoid receptor gene. Glucocorticoid-resistance enables this immunotherapeutic to function in the presence of high doses of steroids which are used post-surgery in glioblastoma treatment and ordinarily inhibit T-cell function. Additionally, SB-728 is a ZFN-based approach for modification of the gene encoding CCR5, the major co-receptor used by HIV to infect cells of the immune system.
Sangamo was founded in 1995 and trades on the Nasdaq Global Market (SGMO). Sangamo is headquartered in Richmond (California, USA). Management Team is composed by Edward Lanphier, Geoffrey Nichol, Ward Wolff, David Ichikawa, Dale Ando and Philip Gregory. Board of Directors is composed by William Ringo, Paul Cleveland, Stephen Dilly, Edward Lanphier, John Larson, Steven Mento, Stewart Parker and Saira Ramasastry. Its Scientific Advisory Board is comprised by experts in molecular biology, structural biology, biochemistry and gene expression and includes some of the pioneers in the field of zinc finger DNA binding protein research: Judith Campisi, Barrie Carter, Michael Gilman, Sir Aaron Klug, Gabor Rubanyi, Kevin Struhl and Keith Yamamoto.
More about Sangamo : www.sangamo.com